InMed Pharma (INM): Broker Consensus Forecast

This price chart on the GURU.Markets platform for InMed Pharmaceuticals (INM) illustrates the asset's dynamics, with a metric of 470.40. InMed Pharmaceuticals (INM) brings together leading chemists to create unique compounds within a flexible scientific environment. The business's financial stability relies on the success of clinical trials, as it currently generates no revenue. Project development remains independent of broader economic trends, focusing instead on the treatment of ocular and skin pathologies.

INM InMed Pharmaceuticals Inc: Price Target Chart in the range 07/04/2022 - 11/09/2026

Metric breakdowns and analytics for InMed Pharma (INM)

- price and consensus price forecast:

Market Chart inmedpharma.com|INM - Price Target Chart

- stock exchange capitalization data:

Market Capitalization InMed Pharma|INM - Total Company Value

- business book valuation details:

Accounting Value per Share InMed Pharmaceuticals|INM - Company Book Value|Capitalization to Book Value Ratio inmedpharma.com|INM - Company Total Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

INM - Net Profit|Forward Earnings InMed Pharmaceuticals|INM - P/E Multiple|Forward P/E Multiple InMed Pharmaceuticals Inc|INM - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation InMed Pharma|INM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months InMed Pharmaceuticals|INM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months inmedpharma.com|INM - Earnings per share growth in current year|Projected earnings per share growth rate for next year InMed Pharmaceuticals

General company analysis:INM (inmedpharma.com)

The indicator is calculated as the arithmetic mean of target prices from leading analysts, capturing the dynamics of market expectations and shifting sentiment among investment firms. The current consensus target price allows for a real-time assessment of how much InMed Pharmaceuticals (INM) patent potential in cannabinoid biosynthesis is priced in, helping to distinguish a true trend reversal from a short-term bounce in biopharmaceutical sector stocks.

Competitors of InMed Pharmaceuticals